Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
2027. jan. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
β-elemene suppressed EMT via IGF1R inhibition in osimertinib treated AXL low-expressing EGFR mutant non-small cell lung cancer.
2026. nov. 2.· European journal of pharmacology· PUBMED
Publikáció
GPR183 senses 7α,25-OHC to drive Treg differentiation and tumor immune evasion via AXL-JAK2-STAT5 signaling.
2026. okt. 30.· Science advances· PUBMED
Publikáció
AXL-directed antibody-drug conjugate therapy in soft-tissue sarcoma.
2026. okt. 16.· Journal of hematology & oncology· PUBMED
Publikáció
Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression.
2026. okt. 13.· Life sciences· PUBMED
Publikáció
AXL and enolase 2 associate with therapy resistance to tyrosine kinase inhibitors lenvatinib and cabozantinib in renal cancer cells.
2026. okt. 13.· Journal of proteomics· PUBMED
Publikáció
Intercellular GAS6-AXL signaling triggers podocyte cuproptosis in acute kidney injury upstream regulated by CEBPD.
2026. okt. 9.· PloS one· PUBMED
Publikáció
Targeting the EpCAM-AXL axis to overcome drug resistance in lung cancer.
2026. okt. 6.· Molecular oncology· PUBMED
Publikáció
AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.
2026. szept. 25.· iScience· PUBMED
Publikáció
Mechanistic insights into VSIR-mediated AXL regulation and gastric cancer proliferation.
2026. szept. 18.· iScience· PUBMED
Publikáció
AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
2026. szept. 18.· Biochemical pharmacology· PUBMED
Preprint
ZNF217 promotes receptor tyrosine kinase plasticity and AXL-ERK dependency in ovarian cancer.
2026. szept. 14.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
SERINC2-mediated phosphatidylserine remodeling activates protrusion-localized AXL signaling to promote brain metastasis.
2026. szept. 10.· Cell reports· PUBMED
Publikáció
The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.
2026. szept. 9.· Frontiers in immunology· PUBMED
Publikáció
Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.
2026. szept. 5.· Molecular cancer therapeutics· PUBMED
Publikáció
Correction: Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
2026. szept. 1.· Acta pharmacologica Sinica· PUBMED
Publikáció
TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway.
2026. aug. 25.· Acta pharmaceutica Sinica. B· PUBMED
Publikáció
Correction: Song et al. AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression. Cancers 2020, 12, 2757.
2026. aug. 18.· Cancers· PUBMED
Publikáció
1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.
2026. aug. 12.· Cells· PUBMED
Preprint
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.
2026. aug. 11.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer.
2026. júl. 20.· Cell reports· PUBMED
Publikáció
RETRACTED: Yen et al. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. Int. J. Mol. Sci. 2017, 18, 372.
2026. júl. 8.· International journal of molecular sciences· PUBMED
Publikáció
[Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway].
2026. júl. 6.· Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences· PUBMED
Publikáció
Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.
2026. júl. 6.· Bone research· PUBMED
Publikáció
RETRACTED: Zito Marino et al. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. J. Pers. Med. 2022, 12, 1993.
2026. jún. 30.· Journal of personalized medicine· PUBMED
Publikáció
Receptor-Ligand Biomarker Profile in Ankylosing Spondylitis: Associations Between AXL/MERTK Expression, Circulating GAS6 and Protein S Levels, and Disease Activity.
2026. jún. 26.· Life (Basel, Switzerland)· PUBMED
Publikáció
Discovery of potential AXL inhibitors using virtual screening, molecular docking, molecular dynamics, molecular mechanics, and in vitro validation.
2026. jún. 23.· Scientific reports· PUBMED
Publikáció
C3+ cancer-associated fibroblast-derived GAS6 promotes cervical cancer metastasis via activation of AXL signaling pathway in a syngeneic orthotopic mouse model.
2026. jún. 8.· Journal of translational medicine· PUBMED
Publikáció
AXL-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer.
2026. máj. 28.· Cancers· PUBMED
Publikáció
Association of Serum AXL and Gas6 Levels with Clinical Outcomes in Non-Hodgkin Lymphoma Patients with Post-Chemotherapy Infection.
2026. máj. 25.· Infection and drug resistance· PUBMED